Cancer Family
Bone Marrow Neoplasm
CI-CAN-00000093Explore in graph →
Non-malignant1,034 active trials28 approved drugs633 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000093Explore in graph →
Clinical trials
4,612 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06398457 | Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies | recruiting | Early Phase 1 | 8 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07059975 | UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML | recruiting | Early Phase 1 | 36 | Baylor College of MedicineOTHER |
| 1 |
| Aug 24, 2026 |
| clinicaltrials |
| NCT07771803 | A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)(Soursop) | recruiting | Early Phase 1 | 20 | Roger StrairOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT03964506 | Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant | recruiting | Early Phase 1 | 24 | Omar AljitawiOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT04187703 | 5-Azacitidine and Decitabine Epigenetic Therapy for Myeloid Malignancies | recruiting | Early Phase 1 | 20 | Benjamin TomlinsonOTHER | 1 | May 18, 2026 | clinicaltrials |
| NCT07071155 | Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia(M-HArbOr) | recruiting | Early Phase 1 | 18 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT07144020 | Donor Derived CD117 CAR-T Cells in the Treatment of R/R Acute Myeloid Leukemia | recruiting | Early Phase 1 | 50 | Zhejiang UniversityOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT07126782 | The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT | recruiting | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 17, 2025 | clinicaltrials |
| NCT06980155 | XP-005 Personalized Vaccine Alone or in Combination With Toripalimab for the Prevention of Relapse After Remission in Acute Myeloid Leukemia | recruiting | Early Phase 1 | 60 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT06201247 | Off-the-shelf CD123 CAR-NK for R/R AML | recruiting | Early Phase 1 | 12 | Peking University People's HospitalOTHER | 1 | Mar 11, 2025 | clinicaltrials |
| NCT06760260 | Evaluation of the Safety and Efficacy of Human CI-135 (FLT3) Targeted CAR-T Cells Injection for Subjects with Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 7 | Hrain Biotechnology Co., Ltd.INDUSTRY | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06762132 | A Clinical Study to Explore the Safety and Efficacy of CD33 CAR-T Cell in Relapsed/Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 27 | Zhejiang UniversityOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT06642025 | EX02 CAR-T Cells for Relapsed and Refractory Acute Myeloid Leukemia | recruiting | Early Phase 1 | 9 | Zhimin ZhaiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04662294 | CD 70 CAR T for Patients With CD70 Positive Malignant Hematologic Diseases | recruiting | Early Phase 1 | 108 | Zhejiang UniversityOTHER | 1 | Nov 4, 2021 | clinicaltrials |
Data updated 5 days agoSource updated Sep 24, 2026source: clinicaltrials